Seaport Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio
Seaport Therapeutics, Inc. Common Stock cash flow-to-debt ratio. Seaport Therapeutics, Inc. Common Stock (SPTX) has a Cash Flow-to-Debt Ratio of -1.37x as of June 2026, meaning its operating cash flow of $-26.14 Million could theoretically repay -1% of its total liabilities ($19.08 Million) in one year. See SPTX free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Seaport Therapeutics, Inc. Common Stock (2024–2025)
Cash flow-to-debt ratio of Seaport Therapeutics, Inc. Common Stock from 2024 to 2025. Historical debt coverage capacity for Seaport Therapeutics, Inc. Common Stock across 2 annual periods. Also explore how fast is Seaport Therapeutics, Inc. Common Stock growing its equity to track the company's year-over-year net asset growth rate.
Seaport Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2024–2025)
Seaport Therapeutics, Inc. Common Stock cash flow-to-debt ratio by year from 2024 to 2025. Year-by-year debt coverage analysis for Seaport Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see cash flow conversion of Seaport Therapeutics, Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.23x | $-77.94 Million | $341.55 Million | ▼ -162.3% |
| 2024 | -0.09x | $-29.63 Million | $340.63 Million | — |